FibroGen (FGEN) to Release Quarterly Earnings on Monday

FibroGen (NASDAQ:FGEN) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $2.00 million for the quarter.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Performance

NASDAQ:FGEN opened at $0.33 on Friday. The company has a market cap of $33.69 million, a price-to-earnings ratio of -0.27 and a beta of 0.87. The stock’s fifty day moving average price is $0.34 and its two-hundred day moving average price is $0.41. FibroGen has a 52-week low of $0.18 and a 52-week high of $1.74.

Insider Transactions at FibroGen

In other news, Director James A. Schoeneck acquired 250,000 shares of FibroGen stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average price of $0.35 per share, with a total value of $87,500.00. Following the purchase, the director now directly owns 323,722 shares of the company’s stock, valued at $113,302.70. The trade was a 339.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thane Wettig bought 145,000 shares of the stock in a transaction on Monday, March 24th. The stock was purchased at an average cost of $0.35 per share, with a total value of $50,750.00. Following the purchase, the chief executive officer now directly owns 543,329 shares of the company’s stock, valued at approximately $190,165.15. This represents a 36.40 % increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on FGEN shares. StockNews.com assumed coverage on FibroGen in a research note on Thursday. They set a “hold” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research note on Tuesday, April 1st. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of FibroGen in a research note on Tuesday, March 18th.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.